New drug ES014 targets desmoid tumors in Mid-Stage trial

NCT ID NCT07541430

Recruiting now Disease control Sponsor: Elpiscience (Suzhou) Biopharma, Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial is testing a drug called ES014 in 50 adults with desmoid tumors, a type of non-cancerous but often painful growth. The drug is given as an IV infusion every two weeks. The main goal is to see if the tumors shrink, while also checking safety and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ES014 (a drug given by IV infusion every 14 days)
What this could lead to: If it works, this could provide a new treatment option to shrink desmoid tumors and improve pain control without surgery.
What could go wrong: This is an early Phase 2 study with only 50 participants and no comparison group, so results may not confirm effectiveness. Side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DESMOID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

desmoid tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DESMOID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.